| Literature DB >> 34755922 |
Hongwei Cheng1, Xiaoshan Fan2, Enyi Ye3, Hu Chen1, Jing Yang4, Lingjie Ke5, Mingliang You6, Minting Liu5, Yong-Wei Zhang4,7, Yun-Long Wu5, Gang Liu1, Xian Jun Loh3,7, Zibiao Li3,7.
Abstract
Aberrant glucose metabolism and immune evasion are recognized as two hallmarks of cancer, which contribute to poor treatment efficiency and tumor progression. Herein, a novel material system consisting of a glucose and TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxyl) at the distal ends of PEO-b-PLLA block copolymer (glucose-PEO-b-PLLA-TEMPO), is designed to encapsulate clinical therapeutics CUDC101 and photosensitizer IR780. The specific core-shell rod structure formed by the designed copolymer renders TEMPO radicals excellent stability against reduction-induced magnetic resonance imaging (MRI) silence. Tumor-targeting moiety endowed by glucose provides the radical copolymer outstanding multimodal imaging capabilities, including MRI, photoacoustic imaging, and fluorescence imaging. Efficient delivery of CUDC101 and IR780 is achieved to synergize the antitumor immune activation through IR780-mediated photodynamic therapy (PDT) and CUDC101-triggered CD47 inhibition, showing M1 phenotype polarization of tumor-associated macrophages (TAMs). More intriguingly, this study demonstrates PDT-stimulated p53 can also re-educate TAMs, providing a combined strategy of using dual tumor microenvironment remodeling to achieve the synergistic effect in the transition from cold immunosuppressive to hot immunoresponsive tumor microenvironment.Entities:
Keywords: glucose targeting; modal imaging; photoimmunotherapy; radical copolymers; tumor microenvironment remodeling
Mesh:
Substances:
Year: 2021 PMID: 34755922 DOI: 10.1002/adma.202107674
Source DB: PubMed Journal: Adv Mater ISSN: 0935-9648 Impact factor: 30.849